脂质体阿霉素在卵巢癌二线化疗中的应用
摘要
脂质体阿霉素作为一种抗癌靶向性的新剂型化疗药物,具有有作用时间长、局部浓度高、毒副作用小等优点。临床试验证实,最大耐受剂量为30～50mg/m2,主要毒副作用有手足综合征、黏膜炎、骨髓抑制;对复发和难治性卵巢癌有一定的作用,特别是对铂类敏感患者,生存期及总费用较应用拓扑替康有明显优势,但对铂类耐药患者却不能提高生存率。脂质体阿霉素在卵巢癌二线化疗中有确定疗效熏并有望成为卵巢癌一线药物之一。
出处
《国外医学（妇产科学分册）》
2005年第3期192-194,共3页
Foreign Medical Sciences(Obstet Gynecol Fascicle)
参考文献20
-
1Romanini A, Tanganelli L, Carnino F. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. Gynecol Oncol, 2003,89(3):354-359.
-
2Perkins WR, Ahmad I, Li X. Novel therapeutic nano-particles (lipocores) : trapping poorly water soluble compounds.Int J Pharm,2000,200(1):27-39.
-
3Gabizon AA. Pegylated liposomal doxorubicin : metamorphosis of an old drug into a new form of chemotherapy.Cancer Invest, 2001,19(4):424-436.
-
4Sadzuka Y. Characterization and Cytotoxicity of Mixed PEG-DSG modified liposomes. Yakugaku Zasshi,2005,125( 1 ): 149 - 157.
-
5Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes : a new Frontier in cancer chemotherapy. J Chemother, 2004,16 [ Suppl 4 ]:94-97.
-
6Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin : review of animal and human studies.Clin Pharmacokinet, 2003,42(5):419-436.
-
7Gokhale PC,Radhadhakrlshnan B,Husain SR,et al.An improved method of encapsulation of doxorubicin in liposomes : Pbarmacological, toxicological, and therapeutic evaluation.Br J Cancer ,1996,74:43-48.
-
8Sakakibara T,Chen FA,Kida H, et al. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.Caneer Res,1996,56:3743-3746.
-
9Sadava D,Coleman A,Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res, 2002,12(4):301-309.
-
10Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyelines : greater cardiac safety versus conventional doxorubicin? Cancer,2004.100( 10 ):2052-2063.
-
1前列腺癌老药有新剂型[J].中国家庭医生,2012(23):55-55.
-
2陈百松,朱小勇,郭银红.紫杉醇联合卡铂二线治疗进展期胃癌的疗效观察[J].中国药房,2010,21(40):3797-3798. 被引量：2
-
3高潺潺.新剂型芬太尼透皮贴剂止痛疗效和安全性分析[J].临床和实验医学杂志,2008,7(2):145-146. 被引量：7
-
4来晓炜,杨林花,侯丽虹,冯建军,张建华.过量服用甲氨蝶呤致严重骨髓抑制一例[J].中国药物与临床,2008,8(10):831-832.
-
5孙建海,顾燕岳,杨水生,马速.多西他赛联合顺铂治疗晚期非小细胞肺癌57例[J].医药导报,2006,25(8):787-788. 被引量：1
-
6李泓,刘天舒.蒽环类药物及其新剂型在晚期胃癌化疗中的价值[J].胃肠病学,2009,14(11):688-690.
-
7龚建忠.非小细胞肺癌脑转移的化疗进展[J].医药前沿,2015,5(26):8-11. 被引量：1
-
8李丹丹,朴金霞,王婷婷.临床完全缓解卵巢上皮性癌CA125界值与预后相关性研究[J].北华大学学报（自然科学版）,2015,16(4):468-470. 被引量：3
-
9王雪梅,沈铿,郎景和.免疫治疗在难治性卵巢癌中的应用[J].现代妇产科进展,1997,6(3):267-270.
-
10谢娟,秦玲,张玉蓉,茅志娟.妇科恶性肿瘤根治术78例行髂内动脉灌注化疗的护理[J].南通大学学报（医学版）,2007,27(4):324-324. 被引量：2
